Shares of Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) jumped 4.11% to ₹923.90 on March 6, 2025, after the company received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Dasatinib tablets in multiple strengths in the U.S.
Key Highlights
- USFDA Approval: Zydus Lifesciences has received final approval to manufacture generic Dasatinib tablets in 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg strengths.
- Drug Details: Dasatinib is a generic version of Sprycel® tablets, which is used to treat Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in newly diagnosed adults.
- Market Size: The total annual U.S. sales for Sprycel® tablets stood at $1,807.7 million, as per IQVIA MAT data (January 2025).
Stock Performance Summary
- Current Price: ₹923.90 (+4.11%)
- Previous Close: ₹887.45
- Day Range: ₹923.90 – ₹923.90
- 52-Week Range: ₹855.10 – ₹1,324.30
- Market Cap: ₹929.66 billion
- P/E Ratio: 20.52
- Dividend Yield: 0.32%
- Average Volume: 1.22 million
Zydus Lifesciences’ latest approval is expected to boost its U.S. sales pipeline and strengthen its position in the oncology segment, making it a key player in the global generics market.
Disclaimer:
The information provided is for informational purposes only and should not be considered as financial or investment advice. Stock market investments are subject to risks, and readers are advised to conduct their own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.
